Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.45 |
| ▸ | GGT1 | P19440 | 2/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704707 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL14677435 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL5704713 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL13224565 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL13746294 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL502878 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL3471145 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL13224526 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL502879 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL12900073 | 0.85 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140271926-A1 | METHODS OF USE OF GLUTAMINE SYNTHETASE INHIBITORS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2014-09-18 | — | — | US | claimed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | L E A F HOLDINGS GROUP LLC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250222001-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-10 | — | — | US | disclosed |
| US-12350271-B2 | Gamma polyglutamated aminopterin and uses thereof | L.E.A.F. HOLDINGS GROUP LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250213578-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2025-07-03 | — | — | US | disclosed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | disclosed |
| US-20030157170-A1 | Micellar drug delivery vehicles and precursors thereto and uses thereof | ANGIOTECH INTERNATIONAL GMBH (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003059408-A2 | SURGICAL PATCHES WITH A BIOLOGICAL ACTIVE AGENT | ANGIOTECH INTERNATIONAL AG (CH) | 2003-07-24 | — | — | WO | disclosed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| EP-1235598-A2 | COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS | Angiotech Pharmaceuticals, Inc. (CA) | 2002-09-04 | — | — | EP | disclosed |
| US-20020055666-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH INTERNATIONAL AG (CH) | 2002-05-09 | — | — | US | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001036007-A2 | COMPOSITIONS OF A COMBINATION OF RADIOACTIVE THERAPY AND CELL-CYCLE INHIBITORS | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319123-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | GGCT, IFNG, FPGS | SLC7A5 1141/4885SLC1A1 1056/4885FOLH1 13/4885 |
| US-20250213578-A1 | ALPHA POLYGLUTAMATED AMINOPTERIN AND USES THEREOF | FOLH1, QPCT, SGTA | SLC7A5 144/4885SLC1A1 118/4885FOLH1 1/4885 |
| US-20030157170-A1 | Micellar drug delivery vehicles and precursors thereto and uses thereof | SLCO1B1, SLCO2A1, BMX | SLC7A5 372/4885SLC1A1 1233/4885FOLH1 2613/4885 |
| US-20250319188-A1 | ALPHA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FPGS, GGCT, FOLR1 | SLC7A5 1020/4885SLC1A1 813/4885FOLH1 7/4885 |
| US-20250222001-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | IFNG, FPGS, MTX1 | SLC7A5 1799/4885SLC1A1 1922/4885FOLH1 20/4885 |
| US-20260053806-A1 | GAMMA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | FPGS, PDF, STOML2 | SLC7A5 202/4885SLC1A1 401/4885FOLH1 23/4885 |
| US-20260130855-A1 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | FOLR2, FPGS, FOLR1 | SLC7A5 890/4885SLC1A1 350/4885FOLH1 8/4885 |
| US-12350271-B2 | Gamma polyglutamated aminopterin and uses thereof | QPCT, SGTA, IFNG | SLC7A5 210/4885SLC1A1 219/4885FOLH1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.